Upload
rudyard-wyatt
View
35
Download
0
Embed Size (px)
DESCRIPTION
American Heart Association Scientific Sessions. Importance of Targeting LDL-C. Trial Designs Compared Statins. Are Statins Enough?. Residual Risk Poorly Managed. PCSK9 Inhibitors. How Low is Too Low?. Please join us as we move on to the next interview. PCSK9 Inhibitors Clinical Trials. - PowerPoint PPT Presentation
Citation preview
American Heart Association Scientific Sessions
Importance of Targeting LDL-C
Trial Designs Compared Statins
Are Statins Enough?
Residual Risk Poorly Managed
PCSK9 Inhibitors
How Low is Too Low?
Please join us as we move on to the next interview.
PCSK9 Inhibitors Clinical Trials
Practicalities of PCSK9 Inhibitors
Few Clinical Barriers
PCSK9 Inhibitors Their Place in the Armamentarium
2013 ACC/AHA Guidelines
Role of PCSK9 Inhibitor in Future Recommendation
Future Drug Therapy
Closing Thoughts
Abbreviations
References
References (cont)
References (cont)